Analysts at Wedbush Reconfirmed their Past ‘Buy’ rating on Shares miRagen Therapeutics Inc (MGEN), Set a $19.0 Price Objective

March 14, 2018 - By Richard Conner

 Analysts at Wedbush Reconfirmed their Past ‘Buy’ rating on Shares miRagen Therapeutics Inc (MGEN), Set a $19.0 Price Objective

miRagen Therapeutics Inc (MGEN) Rating Reaffirmed

In a report revealed to clients and investors this morning, Wedbush maintained their Buy rating on miRagen Therapeutics Inc (MGEN) shares. The PT would indicate a possible upside of 168.74 % from firm’s close price.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Coverage

Among 7 analysts covering Miragen Therapeutics (MGEN), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Miragen Therapeutics has $19.0 highest and $13.0 lowest target. $16.40’s average target is 131.97% above currents $7.07 stock price. Miragen Therapeutics had 11 analyst reports since February 21, 2017 according to SRatingsIntel. Oppenheimer initiated Miragen Therapeutics, Inc. (NASDAQ:MGEN) rating on Thursday, January 11. Oppenheimer has “Buy” rating and $13.0 target. Wedbush maintained the stock with “Buy” rating in Friday, December 1 report. The firm earned “Buy” rating on Monday, August 14 by Chardan Capital Markets. The rating was maintained by Wedbush on Monday, October 16 with “Buy”. The stock of Miragen Therapeutics, Inc. (NASDAQ:MGEN) earned “Buy” rating by FBR Capital on Friday, February 2. On Tuesday, February 21 the stock rating was initiated by Wedbush with “Outperform”. On Friday, August 18 the stock rating was maintained by Wedbush with “Buy”.

The stock increased 0.71% or $0.05 during the last trading session, reaching $7.07. About 223,355 shares traded. Miragen Therapeutics, Inc. (MGEN) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $207.16 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The companyÂ’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.

More notable recent Miragen Therapeutics, Inc. (NASDAQ:MGEN) news were published by: which released: “Miragen Therapeutics May Provide Long-Term Alpha Within The RNA Space” on February 01, 2018, also with their article: “miRagen Therapeutics, Inc. Prices Public Offering of Common Stock” published on February 08, 2018, published: “miRagen Therapeutics to Participate in Upcoming Investor Conferences” on March 05, 2018. More interesting news about Miragen Therapeutics, Inc. (NASDAQ:MGEN) were released by: and their article: “miRagen Therapeutics to Announce Third Quarter 2017 Financial Results and Host …” published on November 01, 2017 as well as‘s news article titled: “miRagen Therapeutics to Report Fourth Quarter and Full Year 2017 Financial …” with publication date: March 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.